Pfizer

Pfizer in 2026 is the textbook deep-value pharma trade. The stock trades at $25.7 — barely 12% above its 10-year low — with a 6.7% dividend yield and a forward P/E of 9. Compared to the COVID-era peak of $59 in December 2021, the equity has lost 56% of its value while the S&P 500 doubled.

The narrative: COVID vaccines and Paxlovid generated a $100B+ revenue boost during 2021-2022 that has fully normalized away. What's left is the underlying base business — and the $43B Seagen acquisition (December 2023), which gives Pfizer the broadest oncology pipeline outside of Roche and Merck. The Seagen ADC (antibody-drug conjugate) franchise booked $5.2B in 2025 and is expected to scale to $10B+ by 2028.

The bear case is the 2028 patent cliff. Eliquis (anticoagulant, $8B revenue) and Ibrance (breast cancer, $4.2B) both face generic competition starting late 2028. Pfizer needs the Seagen pipeline, plus the still-unproven obesity franchise (danuglipron Phase 3 data in 2026), to fill a $12B+ revenue hole. The dividend coverage ratio is currently 78% — uncomfortably tight.

Michael Burry's Scion Asset Management disclosed a fresh long PFE position in the Q4/2025 13F (2.1M shares, ~$54M) — historically rare for Burry, who typically uses 13F-reportable puts for shorts. The position size is consistent with a classic deep-value bet on a beaten-down dividend stock, not a tactical trade.

Other notable smart-money: Stanley Druckenmiller's Duquesne added 5.4M shares in Q1/2026 (~$140M position). Bridgewater added across the All-Weather family by 8M shares. Notable seller: Pershing Square (Ackman) exited his entire 18M-share position in Q3/2025 — Ackman called the patent cliff 'too steep to underwrite' on the December 2025 CNBC interview.

Insider activity (Form 4): CEO Albert Bourla bought 50,000 shares in November 2025 at $24.80 — his first open-market purchase as CEO. CFO David Denton also bought 25,000 shares at $25.10. Two insider buys in 12 months is the bullish tell pharma investors look for, especially after a 50%+ drawdown.

Pfizer trades at a forward P/E of 9.0× and EV/EBITDA of 7.6× as of May 2026 — the lowest valuation among the major Big Pharma names (J&J 15×, Merck 13×, Eli Lilly 38×). The valuation gap reflects the 2028 patent cliff and the unresolved danuglipron binary risk. The bull case (Citi, JP Morgan) values Pfizer's Seagen-led oncology business alone at $80-90B — implying that the rest of the business is being priced near zero. The bear case (Morgan Stanley) argues the patent cliff will deliver three consecutive years of negative EPS revisions, capping the multiple at 8-9× through 2028. Wall Street targets range from $24 (Morgan Stanley) to $36 (Citi), median $29 vs. current $25.7 — 13% upside before the 6.7% dividend.

1. July 30, 2026: Q2/2026 earnings — Seagen revenue growth must exceed 35% to maintain bull thesis
2. October 2026: Danuglipron obesity Phase 3 readout — binary event with $15B+ peak-sales potential
3. January 2027: Pfizer JPMorgan Healthcare Conference presentation — pipeline framework for the 2028 cliff replacement is the key narrative

Pfizer is the most interesting risk-asymmetric pharma trade in the market right now — and also the most easily oversimplified. The 6.7% dividend yield is real, the Seagen pipeline is real, and the insider buying is real. But the patent cliff is also real, and the danuglipron binary risk is real. I treat PFE as a position-sized 'value-plus-yield' play: 1-2% portfolio weight, accept that the next 18 months can deliver -20% or +30% depending on October 2026 data, and let the 6.7% dividend keep me from selling on noise. My add-trigger is below $23 (forward P/E 8 with the dividend pulling yield to 7.5%) — at which point even a 30% dividend cut still beats most fixed-income alternatives.